Arkema to Build Emulsion Polymer Plant in China

Arkema has announced the construction of a latex plant in China to produce a range of emulsion polymers for use primarily in the coatings and adhesives markets. Arkema will invest $30 million in the new plant located on its Changshu platform. Start-up is expected in late 2012.

"Building an Arkema Emulsion Systems facility in China is an important milestone for our business," said Richard Jenkins, Managing Director of Arkema Emulsion Systems Business Unit. "The Changshu facility will allow us to support our global customers who are operating in, or expanding into, the region. This investment represents our first step toward establishing Arkema Emulsion Systems as a multi-national latex supplier. We will continue to explore expansion opportunities that will allow us to better serve our global customers."

Expanding manufacturing into China for emulsion products enhances Arkema's position as an integrated global raw materials source for its customers in many industries, and reinforces Arkema's strategy to grow its position in Asia and increase its acrylics downstream integration. Adding capability for emulsion products will further enhance Arkema's offering in the region to coatings manufacturers, especially after the completion of the Coatex acrylic polymer plant which is expected to start up mid 2011 as announced in July 2009.

Emulsion polymer products (latexes) are used in interior and exterior architectural coatings, elastomeric roof and wall coatings, traffic marking paints; sealant and construction products, and pressure-sensitive adhesives for tapes and labels.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.